All In Biotech

Drug Trial Radar · NCT06073093

A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis

A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis

Last checked: Nov 19, 2026Latest source record: Jul 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 264 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

264

Actual

Start

Nov 7, 2023

Primary completion

Jun 18, 2025

Study completion Jul 2, 2025

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Oct 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a parallel group, Phase 2, randomized, double-blind, placebo controlled, 5-arm, international, multicenter, 12-week proof of concept, dose finding study. It is designed to assess efficacy and safety of treatment with SAR441566 for 12 weeks. It will be conducted in male and female adult participants with moderate-to-severe rheumatoid arthritis (RA) not adequately controlled on methotrexate (MTX) and biologic/targeted synthetic disease modifying anti-rheumatic drug (DMARD) naive. Study treatment includes investigational medicinal product (IMP: SAR441566 or placebo) added-on to a background therapy of MTX. Study details include a run-in period (4 to 6 weeks) before randomization to determine eligibility, a treatment period (12 weeks ± 3 days) and a post-treatment period (safety follow-up) (2 weeks ± 3 days). The total number of scheduled study visits will be 8.

Conditions

  • Rheumatoid Arthritis

Interventions

  • SAR441566Drug

    Tablet

  • PlaceboDrug

    Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants achieving at least 20% improvement from baseline in the American College of Rheumatology (ACR) score at week 12Time frame: Baseline to Week 12

Locations

102 sites in 19 countries. Site status is shown where the registry gives one.

  • Amicis Research Center - Northridge - Nordhoff Street- Site Number : 8400023

    Northridge, California

  • Inland Rheumatology & Osteoporosis Medical Group- Site Number : 8400004

    Upland, California

  • UF Health Deerwood Park- Site Number : 8400020

    Jacksonville, Florida

  • Life Clinical Trials- Site Number : 8400028

    Margate, Florida

  • Future Care Solution - Miami- Site Number : 8400019

    Miami, Florida

  • Innovia Research Center, Inc- Site Number : 8400026

    Miramar, Florida

  • Integral Rheumatology and Immunology Specialists- Site Number : 8400010

    Plantation, Florida

  • Clinical Research of West Florida - Tampa - North Howard Avenue- Site Number : 8400017

    Tampa, Florida

  • Inspire Santa Fe Medical Group- Site Number : 8400029

    Santa Fe, New Mexico

  • Arthritis and Osteoporosis Consultants of the Carolinas- Site Number : 8400012

    Charlotte, North Carolina

  • Carolina Specialty Care- Site Number : 8400007

    Statesville, North Carolina

  • Altoona Center for Clinical Research- Site Number : 8400002

    Duncansville, Pennsylvania

  • Low Country Rheumatology- Site Number : 8400018

    Summerville, South Carolina

  • American Indian Clinical Trials Research Network - Rapid City- Site Number : 8400022

    Rapid City, South Dakota

  • Prolato Clinical Research Center- Site Number : 8400021

    Houston, Texas

  • AARA Clinical Research - Lone Star Arthritis & Rheumatology Associates - Irving- Site Number : 8400031

    Irving, Texas

  • Perceptive Pharma Research- Site Number : 8400009

    Richmond, Texas

  • Investigational Site Number : 0320003

    Buenos Aires, Argentina

  • Investigational Site Number : 0320007

    Buenos Aires, Argentina

  • Investigational Site Number : 0320006

    Mar del Plata, Argentina

  • Investigational Site Number : 0320002

    San Miguel de Tucumán, Argentina

  • Investigational Site Number : 0320002

    San Miguel de Tucumán, Argentina

  • Investigational Site Number : 0320005

    Berazategui, Buenos Aires, Argentina

  • Investigational Site Number : 0320004

    Buenos Aires, Buenos Aires F.D., Argentina

  • Investigational Site Number : 0320001

    Buenos Aires, Buenos Aires F.D., Argentina

  • Hospital São Lucas Copacabana- Site Number : 0760007

    Rio de Janeiro, Brazil

  • CCBR / IBPClin - Instituto Brasil de Pesquisa Clínica- Site Number : 0760005

    Rio de Janeiro, Brazil

  • Centro Paulista de Investigaçăo Clínica - CEPIC- Site Number : 0760001

    São Paulo, Brazil

  • Centro Mineiro de Pesquisa- Site Number : 0760003

    Juiz de Fora, Minas Gerais, Brazil

  • Centro de Estudos em Terapias Inovadoras- Site Number : 0760004

    Curitiba, Paraná, Brazil

  • Investigational Site Number : 1240006

    Calgary, Alberta, Canada

  • Investigational Site Number : 1240001

    Brampton, Ontario, Canada

  • Investigational Site Number : 1240004

    Windsor, Ontario, Canada

  • Investigational Site Number : 1240002

    Sherbrooke, Quebec, Canada

  • Investigational Site Number : 1520009

    Santiago, Chile

  • Investigational Site Number : 1520001

    La Serena, Coquimbo Region, Chile

  • Investigational Site Number : 1520003

    Osorno, Los Lagos Region, Chile

  • Investigational Site Number : 1520005

    Valdivia, Los Ríos Region, Chile

  • Investigational Site Number : 1520002

    Talca, Maule Region, Chile

  • Investigational Site Number : 1520004

    Santiago, Reg Metropolitana de Santiago, Chile

Showing 40 of 102 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.